Cormedix

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

marvell technology shutter

News

Intraday Update

Markets

Movers

Trading Ideas

AAOI

AAPL

ALHC

CRMD

CVNA

GRAB

MRVL

NVDA

PCRX

RYTM

SHOP

SNDK

TSLA

UXIN

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday

Nasdaq index

Equities

Eurozone

Commodities

CNSP

DATS

FUFU

MURA

TNON

Nasdaq Gains 50 Points, US New Home Sales Rise In February

WallStreet.Banks.Shutterstock

Earnings

Price Target

CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Cormedix Inc

Press Releases

CorMedix Inc. Added to Nasdaq Biotechnology Index

General

CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update

Health Care

CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Legal

INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC

Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Arvinas

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Evolus

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Harrow

LENZ Therapeutics

Maze Therapeutics

Nuvation Bio

Omeros

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Tilray Brands

Trevi Therapeutics

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Needham

D. Boral Capital

RBC Capital

Leerink Partners

Truist Securities

Comments

Cormedix

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell